Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Non-Current Debt (2020 - 2023)

Historic Non-Current Debt for Evoke Pharma (EVOK) over the last 4 years, with Q4 2023 value amounting to $5.0 million.

  • Evoke Pharma's Non-Current Debt changed 0.0% to $5.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.0 million for FY2023, which is 0.0% changed from last year.
  • Per Evoke Pharma's latest filing, its Non-Current Debt stood at $5.0 million for Q4 2023, which was down 0.0% from -$5.0 million recorded in Q3 2023.
  • Over the past 5 years, Evoke Pharma's Non-Current Debt peaked at $5.0 million during Q4 2020, and registered a low of -$5.0 million during Q2 2023.
  • Moreover, its 4-year median value for Non-Current Debt was $5.0 million (2020), whereas its average is $3.3 million.
  • In the last 5 years, Evoke Pharma's Non-Current Debt soared by 15000.0% in 2021 and then crashed by 20000.0% in 2023.
  • Over the past 4 years, Evoke Pharma's Non-Current Debt (Quarter) stood at $5.0 million in 2020, then changed by 0.0% to $5.0 million in 2021, then changed by 0.0% to $5.0 million in 2022, then changed by 0.0% to $5.0 million in 2023.
  • Its Non-Current Debt stands at $5.0 million for Q4 2023, versus -$5.0 million for Q3 2023 and -$5.0 million for Q2 2023.